vs
Side-by-side financial comparison of COPT DEFENSE PROPERTIES (CDP) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
COPT DEFENSE PROPERTIES is the larger business by last-quarter revenue ($197.4M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). COPT DEFENSE PROPERTIES runs the higher net margin — 20.0% vs 1.6%, a 18.3% gap on every dollar of revenue. On growth, COPT DEFENSE PROPERTIES posted the faster year-over-year revenue change (7.6% vs 5.0%). Over the past eight quarters, COPT DEFENSE PROPERTIES's revenue compounded faster (1.1% CAGR vs -0.2%).
COPT Defense Properties is a real estate investment trust that invests in office buildings, mostly in the suburbs of the Washington, D.C. metropolitan area. It primarily leases to the U.S. government or companies in the arms industry. As of December 31, 2024, the company owned 164 office buildings comprising 16.5 million square feet and 31 single-tenant data centers comprising 5.9 million square feet.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CDP vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $197.4M | $177.4M |
| Net Profit | $39.4M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 19.9% | 3.9% |
| Net Margin | 20.0% | 1.6% |
| Revenue YoY | 7.6% | 5.0% |
| Net Profit YoY | 8.0% | — |
| EPS (diluted) | $0.32 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $197.4M | $196.9M | ||
| Q3 25 | $188.8M | $179.5M | ||
| Q2 25 | $189.9M | $181.1M | ||
| Q1 25 | $187.9M | $168.9M | ||
| Q4 24 | $183.4M | $187.3M | ||
| Q3 24 | $189.2M | $168.6M | ||
| Q2 24 | $187.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $39.4M | — | ||
| Q3 25 | $43.7M | $5.4M | ||
| Q2 25 | $40.2M | $-4.8M | ||
| Q1 25 | $36.2M | $4.8M | ||
| Q4 24 | $36.5M | — | ||
| Q3 24 | $37.4M | $-143.5M | ||
| Q2 24 | $36.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 19.9% | 1.2% | ||
| Q3 25 | 22.5% | 3.5% | ||
| Q2 25 | 21.0% | 4.7% | ||
| Q1 25 | 19.1% | 1.2% | ||
| Q4 24 | 19.7% | 13.2% | ||
| Q3 24 | 19.8% | -82.8% | ||
| Q2 24 | 19.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 20.0% | — | ||
| Q3 25 | 23.2% | 3.0% | ||
| Q2 25 | 21.1% | -2.7% | ||
| Q1 25 | 19.3% | 2.8% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 19.8% | -85.1% | ||
| Q2 24 | 19.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.32 | $0.05 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.34 | $-0.11 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.31 | $0.38 | ||
| Q3 24 | $0.32 | $-3.11 | ||
| Q2 24 | $0.31 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $275.0M | $144.3M |
| Total DebtLower is stronger | $2.8B | — |
| Stockholders' EquityBook value | $1.5B | $653.9M |
| Total Assets | $4.7B | $1.2B |
| Debt / EquityLower = less leverage | 1.83× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $275.0M | $238.4M | ||
| Q3 25 | $23.7M | $246.3M | ||
| Q2 25 | $21.3M | $445.9M | ||
| Q1 25 | $24.3M | $493.6M | ||
| Q4 24 | $38.3M | $484.6M | ||
| Q3 24 | $34.5M | $453.8M | ||
| Q2 24 | $100.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.8B | $372.2M | ||
| Q3 25 | $2.4B | $376.7M | ||
| Q2 25 | $2.4B | $580.5M | ||
| Q1 25 | $2.4B | $583.4M | ||
| Q4 24 | $2.4B | $585.3M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.5B | $693.1M | ||
| Q3 25 | $1.5B | $727.2M | ||
| Q2 25 | $1.5B | $757.8M | ||
| Q1 25 | $1.5B | $798.5M | ||
| Q4 24 | $1.5B | $778.3M | ||
| Q3 24 | $1.5B | $749.6M | ||
| Q2 24 | $1.5B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.7B | $1.3B | ||
| Q3 25 | $4.4B | $1.3B | ||
| Q2 25 | $4.3B | $1.5B | ||
| Q1 25 | $4.3B | $1.6B | ||
| Q4 24 | $4.3B | $1.6B | ||
| Q3 24 | $4.2B | $1.5B | ||
| Q2 24 | $4.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.83× | 0.54× | ||
| Q3 25 | 1.62× | 0.52× | ||
| Q2 25 | 1.63× | 0.77× | ||
| Q1 25 | 1.62× | 0.73× | ||
| Q4 24 | 1.60× | 0.75× | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $309.9M | — |
| Free Cash FlowOCF − Capex | $288.9M | — |
| FCF MarginFCF / Revenue | 146.4% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | 7.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $501.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $309.9M | $43.7M | ||
| Q3 25 | $68.6M | $60.8M | ||
| Q2 25 | $87.9M | $12.0M | ||
| Q1 25 | $72.1M | $35.5M | ||
| Q4 24 | $331.0M | $33.1M | ||
| Q3 24 | $65.1M | $53.9M | ||
| Q2 24 | $93.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $288.9M | $43.5M | ||
| Q3 25 | $62.9M | $57.0M | ||
| Q2 25 | $84.5M | $9.3M | ||
| Q1 25 | $65.1M | $26.9M | ||
| Q4 24 | $299.6M | $31.0M | ||
| Q3 24 | $61.0M | $49.8M | ||
| Q2 24 | $88.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 146.4% | 22.1% | ||
| Q3 25 | 33.3% | 31.7% | ||
| Q2 25 | 44.5% | 5.1% | ||
| Q1 25 | 34.7% | 15.9% | ||
| Q4 24 | 163.3% | 16.6% | ||
| Q3 24 | 32.3% | 29.6% | ||
| Q2 24 | 47.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 3.0% | 2.2% | ||
| Q2 25 | 1.8% | 1.5% | ||
| Q1 25 | 3.7% | 5.1% | ||
| Q4 24 | 17.1% | 1.1% | ||
| Q3 24 | 2.1% | 2.4% | ||
| Q2 24 | 2.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 7.87× | — | ||
| Q3 25 | 1.57× | 11.20× | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 1.99× | 7.37× | ||
| Q4 24 | 9.08× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 2.58× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CDP
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
